KOL

Quarterly Business Update – March 2023

Retrieved on: 
Thursday, April 27, 2023
KOL, DSM-IV codes, QIAGEN, Partnership, Atrial fibrillation, Q&A, GTG, Marketing, BIM, CIT, ADS, Cardiovascular disease, Pancreatic cancer, American depositary receipt, ASX, MSL, Medical science liaison, Sale, Genetypes, Publication, Poster, Patient, Cancer, Medicine, Consumer, CFO, Growth, BRCA, Health, Ovarian cancer, Breast cancer, Society, Automation, Prostate cancer, Commercial property, Pharmaceutical industry, Melanoma, Breast

MELBOURNE, Australia, April 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, ”Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, releases its Appendix 4C and Quarterly business update for the quarter ending 31 March 2023 (Q3 FY23).

Key Points: 
  • MELBOURNE, Australia, April 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, ”Company”, “GTG”), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, releases its Appendix 4C and Quarterly business update for the quarter ending 31 March 2023 (Q3 FY23).
  • Commenting on the Company’s quarterly performance, Chief Executive Officer Simon Morriss said: “I am pleased to report that we continue to see strong momentum across our business.
  • Our Budget Impact Model (BIM) is a core initiative underpinning the company’s Business to Business strategy.
  • GTG’s CEO, Simon Morriss, and CFO & Company Secretary, Tony Di Pietro will host an investor webinar, to discuss the March 2023 Quarterly Activities Report and hold a Q&A session.

DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis

Retrieved on: 
Thursday, April 27, 2023
Columbia University, Columbia University Irving Medical Center, KOL, Prevalence, Event, Associate, Patient, Biology, Hospital, Alcoholic liver disease, Pharmaceutical industry, AH, Medicine

CUPERTINO, Calif., April 27, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will host a Key Opinion Leader ("KOL") event on Alcohol-Associated Hepatitis on May 16th in New York City.

Key Points: 
  • CUPERTINO, Calif., April 27, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will host a Key Opinion Leader ("KOL") event on Alcohol-Associated Hepatitis on May 16th in New York City.
  • Dr. Paul Gaglio, Professor of Medicine (in Surgery) and director of Hepatology Outreach at NY-Presbyterian Hospital, Columbia University Irving Medical Center.
  • DURECT's KOL Event will also be broadcast online and can be accessed via the following:
    The webcast links will also be available by accessing DURECT's homepage at www.durect.com and clicking on "Events" under the "Investors" section.
  • A replay will be available following the conclusion of the event.

Shofu Dental Brasil, Super-Bond™ Dental Adhesive to Launch in Brazil

Retrieved on: 
Wednesday, April 26, 2023
Chemicals, Plastics, Health, Dental, Manufacturing, TBB, Dentistry, Tetsuo, KOL, Comment, Exhibition, Marketing, Head, Oxygen, SUN, Multimedia, Dentist, Water, Mitsui Chemicals

(Shofu Brasil; Head Office: Sao Paulo, Brazil; President: HARASHIMA Tomomi), a sales subsidiary of SHOFU, will launch Brazilian sales of SUN MEDICAL’s Super-Bond™ dental adhesive in June 2023.

Key Points: 
  • (Shofu Brasil; Head Office: Sao Paulo, Brazil; President: HARASHIMA Tomomi), a sales subsidiary of SHOFU, will launch Brazilian sales of SUN MEDICAL’s Super-Bond™ dental adhesive in June 2023.
  • View the full release here: https://www.businesswire.com/news/home/20230426005025/en/
    Employing 4-methacryloxyethyl trimellitate anhydride (4-META) as a dispersion-aiding monomer and tributylborane (TBB) as a polymerization initiator, Super-Bond™ is an acrylic resin cement made for use as a dental adhesive.
  • Super-Bond™ recently received pharmaceutical approval in Brazil, where the dentistry market looks set for growth going forward.
  • Based on its excellent clinical results so far, we believe that sales of the product will aid dental treatment in Brazil, where minimally invasive surgery has been on the rise.

Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia

Retrieved on: 
Tuesday, April 25, 2023
Molecule, PD, Pharmacogenomics, Drug, Patient, Environment, Neurology, Clinical, BCPP, University, CSO, Allodynia, Parexel, DSM-IV codes, Capsaicin, Magnetic resonance, MRS, RP5063, UV, NGF, FIH, CSF, Serotonin, ChromeOS, Safety, Public key certificate, FCCP, Research, Neurodegenerative disease, KOL, Central nervous system, Drug development, Doctor of Pharmacy, UT, PET, CNS, Bipolar disorder, AD, APEX, Pharmacology, Pharmaceutical industry, Schizophrenia, Psychopharmacology, Depression, Psychiatry, Pharmacy

He will look at brilaroxazine, a next-generation serotonin-dopamine modulator, and its potential as a treatment solution for schizophrenia.

Key Points: 
  • He will look at brilaroxazine, a next-generation serotonin-dopamine modulator, and its potential as a treatment solution for schizophrenia.
  • The Reviva leadership team will provide an overview of the efficacy and safety data generated in the clinical trials completed to date and an update on ongoing RECOVER Phase 3 trial evaluating brilaroxazine in patients with acute schizophrenia.
  • Brilaroxazine is a new chemical entity with broad therapeutic potential in neuropsychiatric and inflammatory conditions arising from underlying dysfunction in serotonin and dopamine signaling.
  • Dr. Ereshefsky’s unique perspective as a clinical scientist (clinical psychiatric pharmacist and psychopharmacologist) helps to guide drug development from preclinical to late Phase.

Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June

Retrieved on: 
Wednesday, April 19, 2023
KOL, Type 2 diabetes, Diabetes, Patient, DSM-IV codes, Cancer, Webcast, Phase, ADA, American Diabetes Association, Safety, Osteopathic medicine in Canada, Pharmaceutical industry

Biomea will disclose additional information about the late-breaking presentation in accordance with ADA’s abstract embargo policies.

Key Points: 
  • Biomea will disclose additional information about the late-breaking presentation in accordance with ADA’s abstract embargo policies.
  • Phase II consists of multiple ascending dose cohorts and includes adult patients with type 2 diabetes uncontrolled by current therapies.
  • In March 2023, Biomea announced initial positive safety and efficacy data for the first two cohorts of patients with type 2 diabetes enrolled in the Phase II portion of the trial.
  • A link to the press release can be found here and a link to webcast can be found here .

MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023
KOL, AACR, Hereditary diffuse gastric cancer, Neoplasm, Cancer, Hope, Research, NSCLC, Cell, Lung cancer, Administration, Cytokine release syndrome, Patient, FOLFOX, Clinical research, Testicular cancer, Mink, Memorial Sloan Kettering Cancer Center, American Association for Cancer Research, Pembrolizumab, Therapy, NIVO, Pharmaceutical industry, Vaccine, Medical device

Allogeneic iNKTs, agenT-797, administered alone or in combination with anti-PD-1 therapy, shows activity in patients with refractory solid tumor cancers.

Key Points: 
  • Allogeneic iNKTs, agenT-797, administered alone or in combination with anti-PD-1 therapy, shows activity in patients with refractory solid tumor cancers.
  • AgenT-797 was administered without toxic lymphodepletion, persists for ~8 weeks, and appears to generate and drive immune cells into the tumor for destruction of cancer cells.
  • HC Wainwright to host KOL webcast with MiNK Therapeutics on Thursday, April 20th at 10:00am ET with Investigators Dr. Benedito Carneiro and Dr. Yelena Janjigian.
  • "Our pioneering off-the-shelf iNKT cell therapy, agenT-797, has demonstrated clinical benefit in solid tumor cancers, and we are committed to expediting its development.

Disc Medicine to Host Disease Webinar with KOLs on Erythropoietic Protoporphyria (EPP)

Retrieved on: 
Thursday, April 13, 2023
San Francisco, KOL, University, EPP, University of California, San Francisco, AURORA, Research, IRON, Patient, Erythropoietic protoporphyria, Porphyria, Paris Diderot University, Epidemiology, Pharmaceutical industry, Gastroenterology

The event will also include an overview of Disc’s development plans of bitopertin for erythropoietic protoporphyria.

Key Points: 
  • The event will also include an overview of Disc’s development plans of bitopertin for erythropoietic protoporphyria.
  • Intended for investors and other interested audiences, the virtual event will feature presentations from leading porphyria experts, who will provide a disease overview and discuss epidemiology, pathophysiology, disease burden, and unmet need associated with EPP.
  • A live webcast of the event will be available in the Events and Presentations section of the Investor page of Disc’s website (https://ir.discmedicine.com/).
  • Please register for the event on the Events and Presentations page of Disc’s website or by clicking this link .

PDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on April 21, 2023

Retrieved on: 
Wednesday, April 12, 2023
KOL, Biotechnology, PDSB, Infection, Cancer, ET, PDS, Interleukin 12, Blood, Webcast, Longevity, Tumor microenvironment, Safety, Pharmaceutical industry

FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced it will host a Key Opinion Leader (KOL) Roundtable on Interleukin-12 (IL-12) for analysts, investors and the scientific community from 8:00 to 9:00 AM, ET on April 21, 2023.

Key Points: 
  • FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced it will host a Key Opinion Leader (KOL) Roundtable on Interleukin-12 (IL-12) for analysts, investors and the scientific community from 8:00 to 9:00 AM, ET on April 21, 2023.
  • This PDS Biotech-sponsored event will focus on the potential of an IL-12 immunocytokine in oncology and the clinical results and promise demonstrated to date with PDS0301, the company’s novel investigational tumor-targeting IL-12 fusion protein.
  • The novel investigational antibody targeted IL-12 enhances the proliferation, potency and longevity of T cells in the tumor microenvironment while also limiting its presence in the blood, which appears to promote tolerability and safety.
  • A replay will be available on the company website for 90 days following the webcast.

Yoshitsu Co., Ltd Implements a KOL Marketing Strategy in the E-commerce Live Streaming Industry and Achieves Business Growth

Retrieved on: 
Tuesday, April 11, 2023
KOL, Marketing, Taobao, Acquisition, Growth, Statista, Principal, Cross-promotion, Social media, Cryptocurrency, Online shopping, TikTok

The effectiveness of KOL marketing has led to a surge in the number of KOLs on social media in China.

Key Points: 
  • The effectiveness of KOL marketing has led to a surge in the number of KOLs on social media in China.
  • Taobao, Douyin, and Kuaishou were three of the leading e-commerce live streaming platforms among Chinese online shoppers.
  • Mr. Mei Kanayama, the Principal Executive Officer of Yoshitsu, commented, “We're confident in our business performance and growth.
  • With our KOL marketing strategy to be established in the e-commerce live streaming industry and based on the financial growth we have achieved so far, we believe that the thriving influencer market in China could bring more business opportunities to us.

Choosing the Right Channel Mix to Maximise KOL Engagement: Featuring AstraZeneca, Gilead, GlaxoSmithKline, Novartis, Sanofi & More - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 5, 2023
Other Professional Services, Professional Services, Thought Leadership, Growth, KOL, Pharma, Noise, Rights, Fatigue, Distribution (marketing), Mobile phone

The "Choosing the Right Channel Mix to Maximise KOL Engagement" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Choosing the Right Channel Mix to Maximise KOL Engagement" report has been added to ResearchAndMarkets.com's offering.
  • Effectively engaging with KOLs is critical to pharma's business and digital communications has become central to building these relationships.
  • But the rapid growth in the number of digital channels has saturated the market leading to KOL digital fatigue.
  • How can you punch through the noise to really get your messages to KOLs?